Manchester BIOGEL: Physiologically Relevant 3d Tissue Models

Top 10 BioTech Startups in Europe - 2021

It is no secret that the COVID-19 pandemic has had a profound influence on the biotech sector. Both startups and established companies have developed rapid diagnostic kits, medicines, and vaccines. To optimize production, the biotech industry is embracing technologies such as artificial intelligence (AI), data analytics, and automation. A wide range of procedures may be automated with the aid of AI in biotech businesses, allowing them to scale up their operations. For example, biopharma startups employ AI to accelerate medication discovery by screening biomarkers and combing through the scientific literature to identify innovative medicines. Image classification algorithms enable the accurate detection of many characteristics, such as cancer cells from medical scans and crop disease indications from leaf photos.

In addition, entrepreneurs are using deep learning to study microbiomes, screen phenotypes, and generate rapid diagnoses. While the majority of the industry’s attention is still on medicine, biotech startups are developing solutions for everything from food to materials to environmental monitoring. At the moment, biotech trends are accelerating the research in biomanufacturing, bioprinting, synthetic biology and precision medicine, among other forthcoming applications.

On that note, a distinguished panel of CEOs, CIOs, VCs, and other thought leaders from the industry, along with the editorial board of Startup City, has selected the leading biotech solution providers looking to offer their expertise to the widest market possible.

In this edition, we present to you StartupCity’s “Top 10 BioTech Startups in Europe - 2021.”

    Top BioTech Startups in Europe

  • Algalif Iceland is an awarded industry leader in production of high quality natural astaxanthin from microalgae. The company supplies high quality natural astaxanthin around the world and is renowned for its reliability and superb quality. Algalif is highly committed to sustainability in its state-of-the-art production facility in Iceland, using only pure natural water, 100 percent renewable Geothermal energy and following both a Zero Waste and Zero Fossil Fuel policies

  • As the planet has evolved exponentially, it has also brought to light the existence of some of the most infectious diseases, making the living beings highly vulnerable

  • Adapttech


    Adapttech is a biomedical company that develops innovative, smart and wearable technologies to help people with physical limitations improve their quality of life

  • BIT Pharma

    BIT Pharma

    Develop and commercialize technologies for site-specific drug delivery to the Central Nervous System, in particular the brain, exploiting tailored drug delivery systems

  • Gyroscope Therapeutics

    Gyroscope Therapeutics

    Gyroscope Therapeutics is a clinical-stage retinal gene therapy company developing gene therapy beyond rare disease to treat a leading cause of blindness, dry age-related macular degeneration (AMD). The fiem's lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. GT005 is designed to restore balance to an overactive complement system by increasing production of the Complement Factor I protein. GT005 is currently being evaluated in a Phase I/II clinical trial called FOCUS and Phase II clinical trials called EXPLORE and HORIZON

  • INBRAIN Neuroelectronics

    INBRAIN Neuroelectronics

    Offers high density and high resolution graphene intelligent neural systems for central and peripheral Neuroelectronic applications

  • Leyden Labs

    Leyden Labs

    Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. The company's portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus families. The Leyden Labs’ energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses

  • LimmaTech Biologics

    LimmaTech Biologics

    LimmaTech Biologics AG is a clinical stage biopharmaceutical company. LimmaTech are a science-driven firm focused on the development and manufacture of next generation pharmaceuticals. The organisation is at the forefront of in vivo carbohydrate engineering. LimmaTech applies its expertise in translating novel scientific concepts into early proof of concepts for the prevention of life-threatening diseases. Additionally, the company develop vaccines together with GlaxoSmithKline plc under an exclusive research and development agreement and conduct its own proprietary research

  • Step Pharma

    Step Pharma

    Step Pharma is developing a novel class of oral nucleotide synthesis inhibitors specifically targeting cytidine triphosphate synthase 1 (CTPS1) to induce selective modulation of T and B cell populations. The discovery of CTPS1 as a potential target for immunomodulation was based on studies of humans with a CTPS1 deficiency (Martin et al., Nature. 2014 Jun 12;510(7504):288-92) providing genetic evidence that CTPS1 inhibition could be used to treat lymphoproliferative cancers and auto-immune diseases. Cytidine nucleotide triphosphate (CTP) is a precursor required for DNA synthesis, a crucial step in cell division. De novo synthesis of CTP depends on two enzymes, the CTP synthases 1 and 2 (CTPS1 and CTPS2). CTPS2 is expressed in most tissues whereas CTPS1 expression is low in all tissues including resting T and B cells, but rapidly and strongly up-regulated specifically in T and B cells following activation

  • TILT Biotherapeutics

    TILT Biotherapeutics

    TILT Biotherapeutics Ltd is a clinical stage company working in the area of enabling tumor T-cell therapy and checkpoint inhibitors with oncolytic viruses. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR-T therapy of solid tumors as currently achieved for CD19+ hematological tumors